Status:
COMPLETED
Gemcitabine (GFF) in Patients With Pancreatic Cancer
Lead Sponsor:
CONKO-Studiengruppe
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Metastatic Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to examine the efficacy and safety of the drug combination GFF in patients with advanced pancreatic cancer (APC).
Detailed Description
This open-label, multi center phase II study was conducted to investigate the efficacy and safety of the combination of 5-Fluorouracil (5-FU)/folinic acid (FA) plus gemcitabine (GFF) in patients (pts)...
Eligibility Criteria
Inclusion
- histological proved pancreatic cancer
- inoperable disease
- informed consent
- adequate bone marrow reserve
Exclusion
- under 18 years
- brain metastasis
- lactating woman
- life expectancy under 3 months
Key Trial Info
Start Date :
September 1 1997
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2002
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT00919282
Start Date
September 1 1997
End Date
December 1 2002
Last Update
June 12 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsmedizin Berlin
Berlin, State of Berlin, Germany, 13353